When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs

1. Goal 3: Ensure healthy lives and promote well-being for all at all ages. In: Sustainable Development Knowledge Platform [Internet]. [cited 28 Jun 2016]. Available: https://sustainabledevelopment.un.org/sdg3

2. Boerma T, Eozenou P, Evans D, Evans T, Kieny M-P, Wagstaff A. Monitoring progress towards universal health coverage at country and global levels. PLoS Med. 2014;11: e1001731. doi: 10.1371/journal.pmed.1001731 25243899

3. Chalkidou K, Glassman A, Marten R, Vega J, Teerawattananon Y, Tritasavit N, et al. Priority-setting for achieving universal health coverage. Bull World Health Organ. 2016;94: 462–467. doi: 10.2471/BLT.15.155721 27274598

4. Teerawattananon Y, Luz A, Kanchanachitra C, Tantivess S. Role of priority setting in implementing universal health coverage. BMJ. 2016;352: i244. doi: 10.1136/bmj.i244 26813049

5. Summers LH. Economists’ declaration on universal health coverage. Lancet. 2015;386: 2112–2113. doi: 10.1016/S0140-6736(15)00242-1 26388531

6. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161: 546–553. doi: 10.7326/M14-0602 25329202

7. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162: 619. doi: 10.7326/M14-1313 25820703

8. Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, Ayer T, et al. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS ONE. 2017;12: e0176503. doi: 10.1371/journal.pone.0176503 28520728

9. Urrutia J, Porteny T, Daniels N. What does it mean to put new hepatitis C drugs on a list of essential medicines? BMJ. 2016;353: i2035. doi: 10.1136/bmj.i2035 27106956

10. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, Joncheere K de, et al. Prices, Costs, and affordability of new medicines for hepatitis C in 30 countries: An economic analysis. PLoS Med. 2016;13: e1002032. doi: 10.1371/journal.pmed.1002032 27243629

11. Andrus JK, Jauregui B, Oliveira LHD, Matus CR. Challenges to building capacity For evidence-based new vaccine policy in developing countries. Health Aff (Millwood). 2011;30: 1104–1112. doi: 10.1377/hlthaff.2011.0361 21653964

12. Kim JJ, Campos NG, O’Shea M, Diaz M, Mutyaba I. Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine. 2013;31, Supplement 5: F60–F72. doi: 10.1016/j.vaccine.2012.07.093 24331749

13. Langley I, Lin H-H, Squire SB. Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. Lancet Glob Health. 2015;3: e83–e84. doi: 10.1016/S2214-109X(14)70370-5 25617201

14. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLoS Med. 2012;9: e1001347. doi: 10.1371/journal.pmed.1001347 23185139

15. ICER Value Assessment Framework–ICER [Internet]. [cited 3 May 2016]. Available: http://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/

16. Wiseman V, Mitton C, Doyle-Waters MM, Drake T, Conteh L, Newall AT, et al. Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks. Health Econ. 2016;25: 140–161. doi: 10.1002/hec.3299 26804361

17. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17: 5–14. doi: 10.1016/j.jval.2013.08.2291 24438712

18. Marshall DA, Douglas PR, Drummond MF, Torrance GW, Macleod S, Manti O, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. PharmacoEconomics. 2008;26: 477–495. 18489199

19. Care SB. Guidance on Budget Impact Analysis of Health Technologies in Ireland. 2015; Available: http://www.hiqa.ie/system/files/Guidance_on_Budget_Impact_Analysis_of_Health_Technologies_in_Ireland.pdf

20. van de Vooren K, Duranti S, Curto A, Garattini L. A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries. Appl Health Econ Health Policy. 2013;12: 33–40. doi: 10.1007/s40258-013-0064-7 24158922

21. NICE International (2014). Bill & Melinda Gates Foundation. Methods for Economic Evaluation Project (MEEP) Final Report.

22. Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, et al. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE. 2016;11: e0168512. doi: 10.1371/journal.pone.0168512 28005986

23. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, DOMI Cholera Economics Study Group. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2009;12: 899–908. doi: 10.1111/j.1524-4733.2009.00562.x 19824189

24. Niëns LM, Zelle SG, Gutiérrez-Delgado C, Rivera Peña G, Hidalgo Balarezo BR, Rodriguez Steller E, et al. Cost-effectiveness of breast cancer control strategies in Central America: the cases of Costa Rica and Mexico. PLoS ONE. 2014;9: e95836. doi: 10.1371/journal.pone.0095836 24769920

25. Basu S, Bendavid E, Sood N. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India. Circ Cardiovasc Qual Outcomes. 2015;8: 541–551. doi: 10.1161/CIRCOUTCOMES.115.001994 26555122

26. Aguilar IBM, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, et al. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Vaccine. 2015;33, Supplement 1: A167–A173. doi: 10.1016/j.vaccine.2014.12.067 25919157

27. Strand KB, Chisholm D, Fekadu A, Johansson KA. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health Policy Plan. 2016;31: 504–513. doi: 10.1093/heapol/czv093 26491060

28. Ortega O, El-Sayed N, Sanders JW, Abd-Rabou Z, Antil L, Bresee J, et al. Cost-Benefit Analysis of a Rotavirus Immunization Program in the Arab Republic of Egypt. J Infect Dis. 2009;200: S92–S98. doi: 10.1086/605057 19817621

29. Kim S-Y, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health. 2010;10: 253. doi: 10.1186/1471-2458-10-253 20470426

30. Goodman CA, Mutemi WM, Baya EK, Willetts A, Marsh V. The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya. Health Policy Plan. 2006;21: 275–288. doi: 10.1093/heapol/czl011 16682433

31. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold [Internet]. University of York, Centre for Health Economics; 2013. Available: http://www.york.ac.uk/media/che/documents/reports/resubmitted_report.pdf

32. Dieleman JL, Templin T, Sadat N, Reidy P, Chapin A, Foreman K, et al. National spending on health by source for 184 countries between 2013 and 2040. Lancet. 2016;387: 2521–2535. doi: 10.1016/S0140-6736(16)30167-2 27086174

33. Kuznik A, Lamorde M, Nyabigambo A, Manabe YC. Antenatal Syphilis Screening Using Point-of-Care Testing in Sub-Saharan African Countries: A Cost-Effectiveness Analysis. PLoS Med. 2013;10. doi: 10.1371/journal.pmed.1001545 24223524

34. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford University Press; 2005.

35. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276: 1253–1258. 8849754

36. Ahmeti A, Preza I, Simaku A, Nelaj E, Clark AD, Felix Garcia AG, et al. Cost-effectiveness of rotavirus vaccination in Albania. Vaccine. 2015;33, Supplement 1: A201–A208. doi: 10.1016/j.vaccine.2014.12.075 25919162

37. Andrieux-Meyer I, Cohn J, de Araújo ESA, Hamid SS. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health. 2015;3: e676–e677. doi: 10.1016/S2214-109X(15)00156-4 26475012

38. The funding of viral hepatitis: the big question [Internet]. World Hepatitis Summit; 2015. Available: http://www.who.int/hepatitis/news-events/06_the-funding-of-viral-hepatitis.pdf?ua=1

39. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med. 2015;163: 215. doi: 10.7326/M15-0406 26120969

40. Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331: 446–448. doi: 10.1136/bmj.331.7514.446 16110075

41. Shiroiwa T, Sung Y-K, Fukuda T, Lang H-C, Bae S-C, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19: 422–437. doi: 10.1002/hec.1481 19382128

42. Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, et al. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012;10: 137. doi: 10.1186/1741-7015-10-137 23148516

43. Campos NG, Sharma M, Clark A, Kim JJ, Resch SC. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries. PLoS ONE. 2016;11: e0164000. doi: 10.1371/journal.pone.0164000 27711124

44. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine. 2013;31: 3786–3804. doi: 10.1016/j.vaccine.2013.06.060 23830973

45. WHO. Immunization Financing Indicators. In: WHO [Internet]. [cited 13 Jul 2017]. Available: http://www.who.int/immunization/programmes_systems/financing/data_indicators/en/

46. Cunnama L, Sinanovic E, Ramma L, Foster N, Berrie L, Stevens W, et al. Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. Health Econ. 2016;25: 53–66. doi: 10.1002/hec.3295 26763594

47. Baltussen R, Jansen MP, Mikkelsen E, Tromp N, Hontelez J, Bijlmakers L, et al. Priority setting for universal health coverage: We need evidence-informed deliberative processes, not just more evidence on cost-effectiveness. Int J Health Policy Manag. 2016; Available: http://www.ijhpm.com/article_3231_0.html

48. Verguet S, Laxminarayan R, Jamison DT. Universal Public Finance of Tuberculosis Treatment in India: An Extended Cost-Effectiveness Analysis. Health Econ. 2015;24: 318–332. doi: 10.1002/hec.3019 24497185